Premium
Medical management and complications of X‐linked hypophosphatemic vitamin D resistant rickets
Author(s) -
ONO TAEKO,
SEINO YOSHIKI
Publication year - 1997
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1997.tb03628.x
Subject(s) - medicine , hypophosphatemia , hypophosphatemic rickets , nephrocalcinosis , vitamin d and neurology , calcitriol , endocrinology , hypercalciuria , rickets , osteomalacia , hyperparathyroidism , parathyroid hormone , hyperphosphatemia , adverse effect , calcium , kidney
To improve the growth failure, bowed legs, and biochemical and radiological abnormalities in patients with X‐linked hypophosphatemic vitamin D resistant rickets (XLH), combined therapy of phosphate and calcitriol is the best therapeutic approach at present. However, the complications involving combined therapy, such as hypercalcemia, nephrocalcinosis and hyperparathyroidism, are not fully solved. To achieve better control, new therapeutic approaches have been reported recently, for example, growth hormone (GH) or new vitamin D analogs. GH improved linear growth, decreased phosphate reabsorption and increased 1‐α‐hydroxylase activity. Furthermore, 24R, 25‐dihydroxyvitamin D 3 (24,25) improved the bone lesions in hypophosphatemic (Hyp) mice, and also in XLH, without the adverse effects such as hypercalcemia or hypercalciuria compared with 1,25‐dihydroxyvitamin D 3 . These new approaches should be considered for the treatment of patients with XLH.